Log in

Start Your Membership Now

The Food and Drug Administration (FDA) announced it is seeking statements of interest for participation in its TEMPO (Technology-Enabled Meaningful Patient Outcomes) pilot for digital health devices beginning in January 2026.

The FDA plans to select up to 10 manufacturers in each of four specific clinical use areas to participate. The voluntary pilot is designed to promote access to certain digital health devices while safeguarding patient safety. The four clinical use areas are early cardio-kidney-metabolic conditions (eCKM); cardio-kidney-metabolic conditions (CKM); musculoskeletal conditions (MSK); and behavioral health conditions (depression and anxiety).

“The TEMPO pilot marks a . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
Log In
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member
If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

Tagged As: